EA201690666A1 - DRUG COMPOSITION CONTAINING CHOLESTEROL SUCTION INHIBITOR AND CHOLESTEROL BIOSYNTHESIS INHIBITOR - Google Patents

DRUG COMPOSITION CONTAINING CHOLESTEROL SUCTION INHIBITOR AND CHOLESTEROL BIOSYNTHESIS INHIBITOR

Info

Publication number
EA201690666A1
EA201690666A1 EA201690666A EA201690666A EA201690666A1 EA 201690666 A1 EA201690666 A1 EA 201690666A1 EA 201690666 A EA201690666 A EA 201690666A EA 201690666 A EA201690666 A EA 201690666A EA 201690666 A1 EA201690666 A1 EA 201690666A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitor
composition containing
cholesterol
interaction
active ingredient
Prior art date
Application number
EA201690666A
Other languages
Russian (ru)
Other versions
EA034711B1 (en
Inventor
Андраш Фехер
Жольт Жигмонд
Дьёрдь Уйфалушши
Петер Тонка-Надь
Адам Орбан
Моника Адьягош
Original Assignee
Эгиш Дьёдьсердьяр Зрт.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эгиш Дьёдьсердьяр Зрт. filed Critical Эгиш Дьёдьсердьяр Зрт.
Publication of EA201690666A1 publication Critical patent/EA201690666A1/en
Publication of EA034711B1 publication Critical patent/EA034711B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Abstract

Настоящее изобретение относится к фармацевтической композиции, содержащей розувастатин и эзетимиб, в которой взаимодействие активного ингредиента и эксципиента сведено к минимуму, активные ингредиенты присутствуют в разделенных в пространстве или контактирующих физических фазах, и в которой высвобождение активного ингредиента из двух фаз происходит с разделением по времени вероятнее, чем происходит в одно и то же время или начинается с задержкой из одной фазы по сравнению с другой. Следующий аспект настоящего изобретения представляет собой способ уменьшения взаимодействия между активным ингредиентом и эксципиентом или взаимодействия между активными ингредиентами в комбинированной фармацевтической композиции, содержащей несколько твердых фаз, полученных путем прессования, где способ включает регулирование времени распадаемости прессованных твердых фаз, отличающихся друг от друга.The present invention relates to a pharmaceutical composition containing rosuvastatin and ezetimibe in which the interaction of the active ingredient and excipient is minimized, the active ingredients are present in separated in space or in contact physical phases, and in which the release of the active ingredient from two phases occurs with a time division what happens at the same time or starts with a delay from one phase compared to another. A further aspect of the present invention is a method of reducing the interaction between the active ingredient and the excipient or the interaction between the active ingredients in a combination pharmaceutical composition containing several solid phases obtained by pressing, where the method includes controlling the disintegration time of the pressed solid phases that differ from each other.

EA201690666A 2013-09-30 2014-09-30 Medical composition containing a cholesterol absorption inhibitor and cholesterol biosynthesis inhibitor EA034711B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1300564A HU231036B1 (en) 2013-09-30 2013-09-30 Pharmaceutical composition comprising a cholesterol biosynthesis inhibitor and a cholesterol absorption inhibitor
PCT/HU2014/000089 WO2015044698A2 (en) 2013-09-30 2014-09-30 Medical composition containing a cholesterol absorption inhibitor and cholesterol biosynthesis inhibitor

Publications (2)

Publication Number Publication Date
EA201690666A1 true EA201690666A1 (en) 2016-08-31
EA034711B1 EA034711B1 (en) 2020-03-12

Family

ID=89991271

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690666A EA034711B1 (en) 2013-09-30 2014-09-30 Medical composition containing a cholesterol absorption inhibitor and cholesterol biosynthesis inhibitor

Country Status (8)

Country Link
EP (1) EP3052088A2 (en)
CN (2) CN114796148A (en)
BR (1) BR112016006888A2 (en)
EA (1) EA034711B1 (en)
HU (1) HU231036B1 (en)
MX (1) MX2016004021A (en)
UA (1) UA120167C2 (en)
WO (1) WO2015044698A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3243506A1 (en) 2016-05-09 2017-11-15 Adamed sp. z o.o. Pharmaceutical composition
JP2017210455A (en) * 2016-05-27 2017-11-30 ニプロ株式会社 Ezetimibe-containing pharmaceutical composition
CZ2016539A3 (en) 2016-09-05 2018-03-14 Zentiva, K.S. A pharmaceutical composition comprising two different active substances and a method of its preparation
CZ2016538A3 (en) 2016-09-05 2018-03-14 Zentiva, K.S. A pharmaceutical composition comprising two different active ingredients
WO2021019499A1 (en) 2019-07-31 2021-02-04 TECNIMEDE - Sociedade Técnico-medicinal, SA Solid oral multiple-unit immediate release compositions, methods and uses thereof
GR1010183B (en) * 2020-12-14 2022-03-01 Elpen Αε Φαρμακευτικη Βιομηχανια, Solid pharmaceutical forms of atorvastatin and ezetimibe

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006134604A1 (en) * 2005-06-15 2006-12-21 Hetero Drugs Limited Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
JP5467870B2 (en) * 2007-02-09 2014-04-09 アルファファーム ピーティーワイ リミテッド Dosage form containing two or more active pharmaceutical ingredients in different physical forms
WO2009024889A2 (en) * 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
EP2204170A1 (en) * 2008-12-01 2010-07-07 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising ezetimibe and simvastatin
EP2448919A2 (en) * 2009-07-02 2012-05-09 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
CN102548971B (en) * 2009-07-24 2015-09-16 埃吉斯药物股份公开有限公司 The crystal formation I of superstatin zinc salt
EA027578B1 (en) * 2009-07-28 2017-08-31 Эгиш Дьёдьсердьяр Ньильваношан Мюкеде Ресвеньтаршашаг New granulating process and thus prepared granulate
CN102357096A (en) * 2011-09-09 2012-02-22 北京阜康仁生物制药科技有限公司 Statins zinc salt-containing blood fat-reducing composite
PL2844233T3 (en) * 2012-05-01 2020-09-07 Althera Life Sciences, Llc Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
MX2012014970A (en) * 2012-12-18 2013-08-27 Hetlabs Mexico S A De C V Pharmaceutical compositions comprising ezetimibe and novel amorphous rosuvastatin calcium.

Also Published As

Publication number Publication date
HUP1300564A2 (en) 2015-04-28
EA034711B1 (en) 2020-03-12
WO2015044698A2 (en) 2015-04-02
EP3052088A2 (en) 2016-08-10
CN105722505A (en) 2016-06-29
CN114796148A (en) 2022-07-29
MX2016004021A (en) 2016-09-06
UA120167C2 (en) 2019-10-25
WO2015044698A3 (en) 2015-05-14
BR112016006888A2 (en) 2017-08-01
HU231036B1 (en) 2019-12-30

Similar Documents

Publication Publication Date Title
EA201690666A1 (en) DRUG COMPOSITION CONTAINING CHOLESTEROL SUCTION INHIBITOR AND CHOLESTEROL BIOSYNTHESIS INHIBITOR
MX2021015106A (en) Novel ferroportin inhibitors.
EA201391318A1 (en) SOLID FORMS 3- (5-AMINO-2-METHYL-4-OXO-4N-KHINAZOLIN-3-IL) PIPERIDIN-2,6-DIONA AND THEIR PHARMACEUTICAL COMPOSITIONS AND APPLICATION
PH12016501724A1 (en) Isoindolinone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
AU2012347200A8 (en) Tablet capable of combatting misuse by injection
EA201692000A1 (en) MACROCYCLIC DERIVATIVES OF PYRIDINE
MX2013003635A (en) N-heteroaryl compounds.
EA201692003A1 (en) MACROCYCLIC DERIVATIVES OF PYRIMIDINE
CY1119542T1 (en) MICRONISM PRODUCT CONTAINING ACUTE ULIPRISTAL
MY174239A (en) Oxazolidin-2-one-pyrimidine derivatives
UA116889C2 (en) COMPOSITION COMPRISING A MIXTURE OF CD95-Fc ISOFORMS
EA201590193A1 (en) LAKVINIMODA PREPARATIONS WITHOUT AN AGENT AGENT
EA201500821A1 (en) Derivatives of 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purines, their use as pharmaceuticals and pharmaceutical compounds
WO2014137797A3 (en) Stable glucokinase activator compositions
MX2018004304A (en) Quinoxaline and pyridopyrazine derivatives as pi3kbeta inhibitors.
WO2014016754A3 (en) Pharmaceutical compositions of proton pump inhibitor
MX2017009289A (en) Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same.
EA201791716A1 (en) PHARMACEUTICAL COMPOSITION
BR112018012043A2 (en) process for reducing sweating
EA201890744A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING 8 - [(3R) -3-AMINO-1-PIPERIDINIL] -7- (2-BUTIN-1-IL) -3,7-DIGIDRO-3-METHYL-1 - [(4-METHYL 2-HINAZOLINIL) METHYL] -1H-PURIN-2,6-DION OR ITS PHARMACEUTICALLY ADAPTABLE SALT
BR112017013031A2 (en) heterocyclyl-linked imidazopyridazine derivatives as pi3kbeta inhibitors
EA201690395A1 (en) STABLE PHARMACEUTICAL COMPOSITION CONTAINING BISOPROLOL AND RAMIPRIL
PH12019500024A1 (en) Pharmaceutical compositions
WO2014159501A3 (en) Processes for preparing tetrahydroisoquinolines
MX350569B (en) Stable pharmaceutical composition for treating osteoporosis.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU

NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): AM AZ BY KZ KG TJ TM RU